BMS signs ADC development deal with Munich-based biotech worth more than $1B

BMS signs ADC development deal with Munich-based biotech worth more than $1B

Submitted by admin on April 20, 2023 - 12:00pm
Source: 
Medical Marketing and Media
News Tags: 
Bristol Myers Squibb
Tubulius
cancer
solid tumors
antibody-drug conjugate
Headline: 
BMS signs ADC development deal with Munich-based biotech worth more than $1B
snippet: 

BMS will have exclusive access to Tubulius’ proprietary P5 conjugation and Tubutecan platforms to develop customizable ADCs for treating cancer and solid tumors.

Do Not Allow Advertisers to Use My Personal information